

- initiation of, 2552
 monitoring of, 2556
 for neurocysticercosis, 903
 overdose/poisoning with, 473e-10t
 for pain, 91t, 94
 pharmacology of, 2553–2555t
 in pregnancy, 2559
 for refractory epilepsy, 2556
 selection of, 2552, 2552t
- Antierythrocyte antibody, 2126t
- Antiestrogens, 530, 530t
- Anti-factor Xa assay, 407, 750, 752
- Antifibrinolytic drugs, 734
- Antifungal agents, **1330**. *See also specific drugs*
 prophylactic, in transplant recipients, 921
 in sepsis/septic shock, 1756, 1757t
 susceptibility testing, 150e-8
 topical, 1331–1332
- Anti-GABA antibodies, 614t, 617
- Anti-GAD antibodies, 614t, 617
- Antigen(s)
 B cell receptor for, 372e-1
 definition of, 372e-1
 macroscopic detection, 150e-2
 minor histocompatibility, 373e-6
 polysaccharide, selective antibody deficiency to, 2112
 red blood cell, 138e-1–2, 138e-1t
 T cell recognition of, 372e-18–19, 372e-18f
 TCR for, 372e-2
- Antigenic drift, 1209–1210, 1209t
- Antigenic shift, 1209, 1209t
- Antigen-presenting cells, 103e-22, 103e-22f
- Antiglomerular basement membrane (anti-GBM) disease
 clinical features of, 1835t, 1839
 genetic considerations in, 1833
 renal biopsy in, 62e-6f, 1839
- Antiglycolipid antibodies, 2695, 2696f
- Antihistamines. *See also specific drugs*
 adverse effects of, 273e-4
 for allergic rhinitis, 2122, 2123f
 for angioedema, 2119
 for atopic dermatitis, 354t
 for contact dermatitis, 354t
 for cough, 244
 for insect stings, 2749
 for insomnia, 191
 for nausea and vomiting, 260
 for otitis media, 230
 overdose/poisoning with, 473e-8t, 473e-13t
 for pityriasis rosea, 349
 as premedication for antivenom, 2737
 for pruritus, 345
 for scombroid poisoning, 2744
 for systemic mastocytosis, 2121
 for vertigo, 151t
- Antihistone antibody, 2126t
- Anti-Hu antibody, 614t, 616
- Anti-Hu paraneoplastic neuropathy, 2700
- Anti-insulin receptor antibodies, 2347t, 2348
- Anti-Jo-1, 2196
- Anti-La antibody, 2126t
- Antileukotrienes, 1678, 1680
- Anti-LGI1 antibodies, 614t, 617
- Antilymphocyte globulin (ALG), 1828
- Antimalarial drugs. *See also specific drugs*
 adverse effects of, 353, 1380t, 2132
 cutaneous, 347, 349, 360, 378, 379, 381
 in GP6D deficiency, 656, 656t
 seizure, 2547t
 for discoid lupus erythematosus, 375
 drug interactions of, 246e-1–2t, 798
 for malaria prophylaxis, 1383t
 for malaria treatment, 1378t
 overdose/poisoning with, 473e-11t, 473e-13t
 in pregnancy and lactation, 246e-1–2t
 properties of, 1380t
 resistance to, 14–15, 1370f, 1379, 1381f, 1384
 for SLE, 2132
 for subacute cutaneous lupus erythematosus, 375
- Anti-Ma proteins, 614t, 616, 616f
- Antimetabolites. *See also specific drugs*
 antibacterial, 931t, 932, 932f
 in cancer chemotherapy, 103e-10–11t, 103e-13–14
- Antimicrobial peptides, 372e-1, 372e-2, 372e-4t
- Antimicrobial stewardship, 918, 945–946, 1026, 1027
- Antimitochondrial antibodies (AMA), 2060
- Antimitotic agents, 103e-11–12t, 103e-14–15.
See also specific drugs
- Antimonial compounds. *See* Meglumine antimonate; Pentavalent antimonials
- Anti-müllerian hormone (AMH), 332, 594, 2376, 2378
- Antimycobacterial agents, **205e-1**. *See also* Tuberculosis, treatment of
- Antimyeloperoxidase (MPO) antibodies, 1840, 2180, 2193
- Antineuronal antibodies, 614, 614t, 2126t
- Antineutrophil antibodies, 418
- Antineutrophil cytoplasmic antibodies (ANCA) cytoplasmic, 2180
 in drug-induced vasculitis, 2193
 in eosinophilic granulomatosis with polyangiitis, 1685, 2180
 in granulomatosis with polyangiitis, 2180, 2184
 in microscopic polyangiitis, 2186
 perinuclear, 2180
 in relapsing polychondritis, 2204
 in vasculitis, 1840, 2180
- Anti-NMDA receptor antibodies, 614t, 615f, 617
- Antinuclear antibodies (ANA)
 in musculoskeletal disease, 2223, 2223t
 in SLE, 2126–2127, 2126t, 2129t, 2131, 2223t
 in systemic sclerosis, 2163
- Antiparasitic agents, **246e-1**, 246e-1–7t. *See also specific drugs*
- Anti-PD-1 agents, 499
- Antiphospholipid antibody(ies)
 classification of, 2135t
 laboratory evaluation of, 406, 2754t
 in SLE, 2126t, 2131
- Antiphospholipid syndrome (APS), **2134**
 in cancer, 613
 classification of, 2135t
 clinical features of, 1835t, 1865, 2135–2136, 2136t
 definition of, 2134–2135
 diagnosis of, 2135t, 2136
 differential diagnosis of, 2136
 epidemiology of, 2135
 high-altitude symptoms of, 476e-4
 pathogenesis of, 372e-24t, 377e-4, 1865, 2135
 renal manifestations of, 1865
 skin manifestations of, 369
 SLE and, 2133
 treatment of, 1865, 2136
- Anti-PL antibodies (aPL), 2135
- α_2 -Antiplasmin, 402f, 403, 758, 758f
- Antiplatelet agents, **745**
 action of, 745–746
 during and after PCI, 296e-2
 chronic use in cardiac disease, 2566t
 in development, 749
 discontinuation before dental procedures, 241–242
 discontinuation before lumbar puncture, 443e-1
 for ischemic heart disease, 1590
 for ischemic stroke, 2563
 for myocardial infarction, 1596, 1598, 1598t, 1606
 perioperative, 54
 for peripheral artery disease, 1644
 for stroke/TIA prevention, 2566t, 2569–2570
- Antiplatelet antibody, 2126t
- Antiporters (exchangers), 332e-6
- Antiprogestins, 2391
- Antiproteinase 3 antibodies, 1840
- Antipsychotics
 action of, 2721
 for acute alcohol intoxication, 2727
 adverse effects of, 2624, 2721–2722, 2722t
- for dementia, 175–176, 2602
 drug interactions of, 2711t
 overdose/poisoning with, 473e-8t, 473e-9t, 473e-12t, 473e-13t
 for schizophrenia, 2721–2722, 2722t
- Antipyretic agents, 126
- Antireflux surgery, 263
- Antiretroviral agents. *See* Combination antiretroviral therapy (cART)
- Anti-Ri antibody, 614t, 618
- Antiribosomal P antibody, 2126t
- Anti-RNP antibody, 2126t, 2757t
- Anti-Ro antibody, 2126t, 2131, 2133
- Anti-Saccharomyces cerevisiae antibodies, 2194
- Anti-Sm antibody, 2126t, 2131
- Antithrombin
 action of, 402, 402f, 405
 activation of, 749, 750f, 752
 deficiency of, 744
- Antithrombotic drugs, 745, 745f
 anticoagulants. *See* Anticoagulant(s)
 antiplatelet agents. *See* Antiplatelet agents
 fibrinolytic drugs. *See* Fibrinolytic drugs
- Antithrombotic mechanisms, 402, 402f
- Antithymocyte globulin (ATG)
 adverse effects of, 2071
 for aplastic anemia, 666–667
 in HSCT preparation, 139e-2
 for immunosuppression after liver transplantation, 2071
 for myelodysplasia, 671
 for paroxysmal nocturnal hemoglobinuria, 662
- Antithyroid drugs, 2296–2297. *See also specific drugs*
- Anti-TNF- α antibodies. *See* Tumor necrosis factor- α (TNF- α) inhibitors
- Antitoxin
 botulinum, 261e-9, 989
 diphtheria, 979
- Anti-Tr antibody, 614t, 618
- α_1 -Antitrypsin, 1706, 1945
- α_1 -Antitrypsin deficiency
 clinical features of
 cutaneous, 366
 granulomatosis with polyangiitis, 1840
 hepatic, 367e-2, 1992, 2062
 pulmonary, 1695, 1700–1701, 1703, 1705
 diagnosis of, 366e-4f, 367e-2, 1993t
 early interventions for, 450t
 epidemiology of, 367e-2
 genetic considerations in, 367e-2, 435
 genetic testing for, 443, 450t
 hepatocellular carcinoma and, 545, 545t
 treatment of, 367e-2
- Antitumor antibiotics, 103e-9–10t, 103e-13
- Antitussive agents, 245
- Antiuricosuric compounds, 431e-1
- Antivenom
 adverse effects of, 2737
 indications for, 2735
 for marine envenomations, 2739
 for scorpion stings, 2748
 for snakebite treatment, 2735, 2736t
 sources of, 2741–2742
- Anti-VGCC antibodies, 614t
- Antiviral therapy, **215e-1**. *See also* Combination antiretroviral therapy (cART); *specific drugs and diseases*
 for hepatitis virus infections, 215e-4–5t, 215e-9–11
 for herpesvirus infections, 215e-2–3t, 215e-6–9
 for respiratory infections, 215e-1, 215e-2t, 215e-5–6
- Anti-Yo antibody, 614t, 618
- Anton's syndrome, 2575
- Antrectomy, for duodenal ulcers, 1925, 1925f
- Anuria, 292
- Anxiety
 definition of, 2708
 erectile dysfunction and, 326
 female sexual dysfunction and, 330
 in respiratory acidosis, 322
 vs. syncope, 147